Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer Population:  ER+, HER2-...

A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab...

The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer):...

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in...

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of...

A Phase 3, Randomized, Multi-center, Open-label Study of DB-1303 Versus Investigator’s Choice Chemotherapy in Human Epidermal Growth...

An Interventional, Open-Label, Randomized, Multicenter Phase 3 Study of PF-07220060 Plus Fulvestrant Compared To Investigator`s Choice of...

Real-World Patient-Reported Outcomes in ER+/HER2- Advanced/Metastatic Breast Cancer Population: ER+/HER2- mBC Line of therapy:  2L...

An Interventional, Open-Label, Randomized, Multicenter Phase 3 Study of PF-07220060 Plus Fulvestrant Compared To Investigator`s Choice of...

An Interventional, Open-Label, Randomized, Multicenter Phase 3 Study of PF-07220060 Plus Fulvestrant Compared To Investigator`s Choice of...